TRIM33 and cancer: Identification of autoantibodies against cancer-associated TRIMs accords with the strong temporal association between myositis and development of malignancies in adult-onset anti-TIF1γ-positive DM4, consistent with the high proportion of cancer-associated myositis cases in the current study (45%), including ovarian, lung and hepatic cancer.